Video: Promoting Herbal Medicines, Producers Request Phytopharmaca Inclusion in BPJS

Jakarta, CNBC Indonesia - Dexa Group, as a leading pharmaceutical company, continues to develop research on phytopharmaca products and Original Indonesian Modern Medicines (OMAI) made from natural ingredients that have been tested for safety and efficacy.

Director of Research and Business Development at Dexa Group, Raymond Tjandrawinata, stated that the increasing trend of returning to nature or ‘back to nature’ has made herbal medicines increasingly popular among people worldwide.

The vast potential of the herbal medicine market as a remedy to aid healing reaches USD 500 billion, with major players from China and India. Meanwhile, Indonesia, as a country with the second-largest biodiversity wealth after Brazil, has only reached USD 5 billion, thus Indonesia has the opportunity to explore broader potential in developing local herbal medicines.

One of Indonesia’s challenges in developing research and expanding the herbal medicine market is the lack of integration of phytopharmaca products or traditional medicines into the national health system. Therefore, strengthening the supply chain for access to herbal medicines in primary health service centres from clinics to hospitals is needed, while encouraging doctors to use phytopharmaca by opening access within BPJS Health.

What steps are required to promote the utilisation of natural ingredient medicines in Indonesia to compete in the global pharmaceutical industry? For more details, watch the dialogue between Maria Katarina and Director of Research and Business Development at Dexa Group, Raymond Tjandrawinata, in Profit CNBC Indonesia (Tuesday, 12/05/2026).